FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person * MPM BIOVENTURES III QP LP					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVE., 31ST FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 05/20/2004						-	Office	r (give title belo	ow)	Other (s	specify belo	ow)		
BOSTON, MA 02199					4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person							
(City) (State) (Zip)						Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
(Instr. 3)		Date (Month/Day/Year) a		Execut any	2A. Deemed Execution Date, if any Month/Day/Year)		Code		4. Securities Acquired (a or Disposed of (D) (Instr. 3, 4 and 5)			I (A)	Benefici	ant of Securities ally Owned Following d Transaction(s) and 4)		Ownership Form: Direct (D)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	7	V	Amount	(A) or (D)	Pr	rice			(I) (Inst		(nsu. 4)
Common Stock 05/20/2		/2004			S			139,313 (1)	D	\$ 17.2	2479	3,536,258		I	F	ootnote			
Reminder:	Report on a s	separate line	for each	n class of sec	urities l	beneficially	owned d		•		_								
								•	CO	ntained ii	n this	form	are i	not requ		formation spond unle trol numbe		SEC 14	174 (9-02)
				Table II		ative Securi								Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year		Execution D		4. Transaction Code	5. Numb of Deriva Securi Acquir (A) or Dispos of (D) (Instr.	Number of (N Derivative Securities Acquired (A) or Disposed		and Expiration Date (Month/Day/Year) A U S		7. Titl Amou Under Secur (Instr. 4)	erlying Security		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficia Ownersh (Instr. 4)	
						Code V	(A)			ate cercisable	Expira Date	ation	Title	Amount or Number of Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MPM BIOVENTURES III QP LP C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199		X					
MPM BIOVENTURES III LP C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199		X					

MPM BIOVENTURES III GMBH & CO C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
MPM BIOVENTURES III PARALLEL FUND C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
MPM BIOVENTURES III GP LP C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
MPM BIOVENTURES III LLC C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
GALAKATOS NICHOLAS C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
STEINMETZ MICHAEL C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	
WHEELER KURT C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVE., 31ST FLOOR BOSTON, MA 02199	X	

Signatures

By Luke Evnin, member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, L.P., the general partner of MPM BioVentures III-QP, L.P /s/ Luke Evnin					
**Signature of Reporting Person					
By Luke Evnin, member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, L.P., the general partner of MPM BioVentures III, L.P /s/ Luke Evnin "Signature of Reporting Person	05/21/2004 Date				
By Luke Evnin, member of MPM BioVentures III LLC, the gp of MPM BioVentures III GP, L.P., the gpof MPM BioVentures III GmbH & Co. Beteiligungs KG /s/ Luke Evnin "Signature of Reporting Person	05/21/2004 Date				
By Luke Evnin, member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, L.P., the general partner of MPM BioVentures III Parallel Fund, L.P /s/ Luke Evnin "Signature of Reporting Person	05/21/2004 Date				
By Luke Evnin, manager of MPM Asset Management Investors 2003 BVIII LLC /s/ Luke Evnin **Signature of Reporting Person					
By Luke Evnin, member of MPM BioVentures III, LLC, the general partner of MPM BioVentures III GP, L.P. /s/ Luke Evnin	05/21/2004				
**Signature of Reporting Person	Date				
By Luke Evnin, member of MPM BioVentures III, LLC /s/ Luke Evnin	05/21/2004				

**Signature of Reporting Person	Date
/s/ Nicholas Galakatos	05/21/2004
Signature of Reporting Person	Date
/s/ Michael Steinmetz	05/21/2004
**Signature of Reporting Person	Date
/s/ Kurt Wheeler	05/21/2004
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- See Form 4 filed for Luke Evnin for additional members of this joint filing. The shares were sold as follows: 7,797 by MPM BioVentures III, L.P. ("BVIII"); 115,967 by

 MPM BioVentures III-QP, L.P. ("BVIII QP"); 9,801 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 3,502 by MPM Bioventures III Parallel Fund,
 L.P. ("BVIII PF"); and 2,246 by MPM Asset Management Investors 2003 BVIII LLC ("BVAM LLC"). MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures

 III LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII FF and BVIII KG.
- The shares are held as follows: 197,925 by BVIII; 2,943,662 by BVIII QP; 248,776 by BVIII KG; 88,902 by BVIII PF; and 56,993 by BVAM LLC. Luke Evnin, Ansbert (2) Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon, III, Michael Steinmetz and Kurt Wheeler are the members of BVIII LLC and BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.